William Blair reiterates Outperform on ARS Pharma stock after FDA label update

Q4 2025 revenue of $28.1M beat the $26.9M forecast and EPS was -$0.41 vs expected -$0.4246; full-year 2025 revenue was $72.2M (consensus ~$73M) with a Q3→Q4 sequential decline to $28.1M from $31.3M due to seasonality. The FDA removed an age restriction for neffy in the 33–66 lb weight range (affecting ~25% of current epinephrine prescriptions), prompting William Blair to reiterate an Outperform and Leerink to raise its price target from $25 to $26; market cap ~ $811M. Analysts maintain a Strong Buy consensus, InvestingPro flags SPRY as trading below fair value and forecasts ~91% revenue growth this year, though cash burn remains a noted risk.

Analysis

The commercial story here is less about clinical efficacy and more about clearing non-clinical friction: formulary placement, PBM economics, and device logistics. If SPRY can materially reduce friction for prescribers and pharmacies, uptake will scale non-linearly because episodic use products live or die on point-of-care convenience and pharmacy stocking — not on marginal efficacy. That makes the next wave of payor and PBM decisions the true gating items; wins there create durable prescription flow while losses push the product into niche use despite good clinical positioning.

Second-order constraints matter: contract manufacturing capacity for combination drug-device formats and the company’s ability to manage gross-to-net (rebates/copay assistance) will determine realized revenue per unit, not just box sales. A successful early launch could invite aggressive incumbent pricing/rebate responses and larger-scale rebate negotiation with specialty pharmacies — a dynamic that can compress gross margins quickly even as top-line grows. Tail risks include a material manufacturing yield issue or a payor class-action over coverage fairness that could take 3–12 months to resolve and materially reset valuation.

Consensus is positioned around straightforward upside from commercialization; the overlooked scenario is effective payor resistance or supply hiccups that force dilution to extend runway. Conversely, a string of formulary wins over 3–9 months would be a high-leverage catalyst because marginal incremental access yields outsized prescription growth in this category. Tactical positioning should therefore be asymmetric: own downside-protected exposure to commercialization optionality while being explicit about dilution and PBM negotiation risk.

Key Decisions for Investors

• Core long equity (SPRY): Initiate a 1–2% portfolio position in SPRY shares with a 12–18 month horizon. Rationale: capture asymmetric upside from formulary wins; risk management: set a 30–35% stop or size reduction trigger tied to a financing/dilution event. Reward view: aim for 2x+ upside if access momentum materializes.
• Defined-risk option spread (SPRY): Buy a 12–18 month call spread to cap premium paid (buy longer-dated LEAP call, sell higher strike) to express bullish commercialization view while limiting downside to the debit. Time entry around post-earnings or when a clear set of PBM decisions is announced to maximize convexity. Expected payoff: 3–6x on premium if multiple formulary wins occur.
• Pair trade (long SPRY / short VTRS): Small, size-neutral pair over 6–12 months to express share-shift potential vs incumbent autoinjector provider (VTRS). This isolates category-share dynamics from broader market moves. Risk: incumbents can out-rebate or broaden distribution; reward: capture relative outperformance if SPRY secures favorable PBM placement.
• Event binary (near-term): Allocate a small, tactical options position (short-dated calls or call spreads) ahead of known PBM/formulary decision windows (3–9 months). Keep exposure <0.5% portfolio — asymmetric payoffs if access wins are announced; downside limited to premium spent.